Concepedia

S. Qin

SQ

Statistics

Publications

2

Citations

49

H-Index

2

Active since

2022

Affiliations

University of Manchester(Current)

Seoul National University Hospital

Wakayama Medical University

Assistance Publique – Hôpitaux de Paris

National Health Research Institutes

S. Qin is an author at University of Manchester specializing in medicine, cancer survival analysis, and targeted combination chemotherapy.

Publications per year

2022–2022

2

Publications

2

78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

D-Y. Oh, A.R. He, S. Qin et al. · Annals of Oncology · 2022 · 26 citations

, , +9

56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

D-Y. Oh, A.R. He, S. Qin et al. · Annals of Oncology · 2022 · 23 citations

, , +10

1–2 of 2